Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs) EQUITY
$61.02
pos +0.30
+0.49%
Today's Range: 60.03 - 61.98 | BMY Avg Daily Volume: 6,482,900
Last Update: 02/09/16 - 4:01 PM EST
Volume: 6,359,433
YTD Performance: -11.73%
Open: $60.27
Previous Close: $60.72
52 Week Range: $51.82 - $70.87
Oustanding Shares: 1,668,286,317
Market Cap: 99,479,913,083
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 7 7
Moderate Buy 1 1 1 1
Hold 6 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.96 1.88 1.81 1.81
Latest Dividend: 0.38
Latest Dividend Yield: 2.55%
Dividend Ex-Date: 12/30/15
Price Earnings Ratio: 29.67
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
29.67 54.50 28.38
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-7.23% 1.76% 63.98%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 -0.25 -0.09
Net Income -21.40 -0.61 -0.27
EPS -22.20 -0.44 -0.18
Earnings for BMY:
EBITDA 3.06B
Revenue 15.88B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $0.64 $0.61 $2.37 $3.07
Number of Analysts 6 4 11 11
High Estimate $0.79 $0.65 $2.46 $3.23
Low Estimate $0.57 $0.58 $2.31 $2.82
Prior Year $0.71 $0.53 $2.01 $2.37
Growth Rate (Year over Year) -9.39% 15.57% 18.14% 29.33%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Bruce Kamich

 | Jan 29, 2016 | 4:58 PM EST

At the end of 2015, BMY looked attractive, but starting 2016, shares turned south along with the overall market. 

bearishBristol-Myers downgraded at BMO

Jan 25, 2016 | 7:39 AM EST

BMY was downgraded from Outperform to Market Perform, BMO Capital said. Valuation call, based on a $70 price target. 

bullishBristol-Myers upgraded at Berenberg

Jan 22, 2016 | 7:44 AM EST

BMY was upgraded from Hold to Buy, Berenberg said. $77 price target. Immuno-oncology franchise should drive growth. 

By

Robert Moreno

 | Dec 10, 2015 | 1:30 PM EST

While others struggle, this stock is testing its all-time high and shows no signs of slowing.

By

Ed Ponsi

 | Dec 9, 2015 | 12:30 PM EST

I chose stocks that I believe present the best investment opportunity right now.

By

Ed Ponsi

 | Dec 9, 2015 | 9:00 AM EST

I picked the stocks that I believe present the best investment opportunity right now.

By

Jim Cramer

 | Dec 1, 2015 | 5:16 AM EST

There's too much good out there.

By

Bruce Kamich

 | Nov 16, 2015 | 3:15 PM EST

CAT not going down on bearish news gets us closer to a bottom and buy recommendation.

By

Jim Cramer

 | Nov 4, 2015 | 3:04 PM EST

Being in the right sector at the wrong time.

By

Bret Jensen

 | Nov 3, 2015 | 10:00 AM EST

Here are some mid-cap names with solid upside potential.

A huge and predictable earnings quarter initially sent Disney (DIS) up after hours but the...

$125 million to sell market on close

We have had some text book timing lately....

The big question now is whether or not the positive divergence between ES (Emini S&P 5...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.